Background: The aim of this study was to evaluate the efficacy and safety of carmustine (BCNU) in combination with temozolomide as first-line chemotherapy before and after radiotherapy (RT) in patients with inoperable, newly diagnosed glioblastoma multiforme (GBM). Patients and methods: Forty patients were treated with BCNU (150 mg/m 2 ) on day 1 and temozolomide (110 mg/m 2 /day) on days 1 through 5 of each 42-day cycle for up to four cycles prior to conventional RT (2 Gy fractions to a total of 60 Gy). After RT, BCNU + temozolomide was administered for four additional cycles or until progression. The primary end point was response rate; secondary end points included progression-free survival (PFS); overall survival (OS) and safety.
Introduction
Glioblastoma multiforme (GBM) represents the most frequent and aggressive type of primary malignant brain tumor, which occurs in 4-6 per 100 000 people. At present, median survival is only 9-12 months. The standard treatment for GBM is surgery, when feasible, followed by radiotherapy (RT) with or without chemotherapy [1] . Patients for whom debulking surgery is not feasible have a poor prognosis.
The modest benefit of chemotherapy in patients with GBM has been widely documented and likely reflects the relative insensitivity of GBM to cytotoxic agents. The value of adjuvant chemotherapy is still under discussion. Numerous cooperative group trials have failed to show a statistically significant survival benefit when adjuvant nitrosourea-based chemotherapy was added to conventional RT [2 -5] . However, a meta-analyses of 12 randomized trials concluded that chemotherapy adds to the benefit of RT in patients with highgrade gliomas [6] . In addition, a recent randomized, phase III trial conducted by the European Organization for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) demonstrated a statistically significant survival benefit compared with RT alone for patients with GBM who were treated with temozolomide concurrently with RT followed by adjuvant temozolomide [7] . These studies suggest that chemotherapy has a role in the treatment of newly diagnosed GBM.
Chemotherapy is most commonly administered after RT. However, alternative options include concomitant administration of chemotherapy and RT as reported in the EORTC/NCIC trial [7] , or administration of chemotherapy before RT (i.e. neo-adjuvant chemotherapy). Studies investigating neo-adjuvant treatment provide an opportunity to test and select new and effective chemotherapy regimens because the true objective response to chemotherapy alone can be observed. Many studies have tested this approach using either single-agent or combination regimens administered for one to four cycles before RT, and have demonstrated objective response rates ranging from 23% to 54% [8 -14] .
Both carmustine (BCNU) and temozolomide have demonstrated activity in malignant gliomas and are widely used for the treatment of GBM. Concomitant treatment with temozolomide and RT demonstrated a median survival of 16 months in a phase II trial [15] and a median survival of 15 months in a phase III trial [7] . Temozolomide has also been investigated as neo-adjuvant therapy, before RT, and in this setting produced response rates of 42% to 51% [10, 14] . In addition to these efficacy data, the safety profile of temozolomide is attractive (<5% grade 4 adverse events), which opens the possibility of combination therapy.
The rationale for combining BCNU and temozolomide is based on the observed synergic activity of these drugs in preclinical models [16] . This may be attributed, at least in part, to the capacity of temozolomide to deplete intracellular levels of O 6 -alkylguanine-DNA alkyltransferase (AGAT) [17] , the DNA repair enzyme involved in resistance to BCNU. The strong relationship between AGAT expression and BCNU resistance suggests that modulation of nitrosourea resistance by depletion of AGAT is a reasonable therapeutic strategy [18, 19] . Unfortunately, preclinical models have not been able to clearly discern the optimal sequence and schedule of administration of BCNU and temozolomide to minimize toxicity and maximize antitumor activity [16, 20] . Various schedules have been evaluated clinically and included administration of both drugs on day 1 as proposed by Plowman et al. [16] , but this regimen resulted in significant toxicity without evidence of any additive antitumor activity in phase I and phase II studies [21] [22] [23] . An alternative schedule involves administration of temozolomide for five consecutive days with BCNU administered on either day 1 or day 5. This was evaluated in a randomized, phase I study, and the results demonstrated sequence-dependent toxicity. Administration of BCNU on day 1 was better tolerated and resulted in a higher tolerated dose of both drugs, as well as a three-fold decrease in AGAT activity [24] . This schedule also demonstrated significant antitumor activity in gliomas, ovarian cancer and sarcomas. These observations are consistent with preclinical models suggesting that administration of BCNU before temozolomide was less toxic and more effective; therefore, we used this schedule of administration in the current study.
The objectives of this study were to evaluate the antitumor activity and tolerability of neo-adjuvant BCNU + temozolomide in patients with unresectable, newly diagnosed GBM. This is a patient population for which optimal treatment has not been defined and prognosis remains extremely poor.
Patients and methods
Newly diagnosed patients with unresectable, histopathologically proven GBM were evaluated for participation in this prospective monocentric study. Histology was obtained by stereotactic biopsy and reviewed by a second pathologist for all patients, and graded according to World Health Organization classification. Eligible patients had to satisfy the following criteria: (i) newly diagnosed GBM not amenable to surgical excision; (ii) no prior radiotherapy or chemotherapy; (iii) 18-70 years of age; (iv) Karnofsky performance status (KPS) of > _ 60; (v) measurable disease based on contrast enhancing lesion on magnetic resonance imaging (MRI); and (vi) adequate hematological, renal and hepatic function. Patients who were pregnant or breast-feeding were ineligible. The protocol was approved by the local medical ethics board, and all patients provided written informed consent.
Treatment plan
Chemotherapy was administered for up to four cycles, repeated every 42 days, followed by RT. Each cycle included temozolomide (110 mg/m 2 ) on day 1 followed 2 h later by BCNU (150 mg/m 2 ) infused over 2 h, and temozolomide (110 mg/m 2 ) on days 2-5. Prophylactic antiemetics using 5-hydroxytryptamine-3 were systematically administered from day 1 to day 5. RT was delivered after four cycles in case of response or stable disease, or earlier in case of tumor progression after the neo-adjuvant chemotherapy period. Focal radiotherapy using a linear accelerator was delivered once daily at 2 Gy per fraction, 5 days/week for a total of 60 Gy. Treatment volumes were determined on the basis of initial gadoliniumenhanced MRI (Gd-MRI) of the brain, and included contrast enhancing lesions plus a 2-to 3-cm margin, depending on tumor volume and location. One month after completion of RT, chemotherapy using the same schedule of BCNU and temozolomide combination was administered for up to four additional cycles, or until progression, unacceptable toxicity or patient refusal. Anticonvulsants were administered as needed, and corticosteroids were used at and adjusted to the optimal dose according to the patient's neurological condition.
Patient evaluation
Baseline evaluations were performed within 14 days (28 days for imaging) from study entry and included complete medical history, physical and neurological examination, determination of KPS and Mini-Mental Status (MMS), hematology and chemistry assessments, and Gd-MRI. During chemotherapy, complete blood counts were checked weekly and blood chemistry was checked every 3 weeks. A physical and neurological examination, KPS, MMS if appropriate, and a Gd-MRI of the brain were performed after each 42-day cycle for the first four cycles, and then before RT and 1 month after completion of RT. During maintenance chemotherapy, clinical evaluation was performed after each cycle, with Gd-MRI performed at least every two cycles.
Statistical analysis
The primary end point of the study was response to treatment. Response was evaluated every cycle for the first four cycles, 4 weeks after completion of radiotherapy, and thereafter at least every two cycles. Response was evaluated according to the Macdonald criteria [25] and based on consecutive Gd-MRI under stable steroid use for 7 days before scan. For evaluation, the slice with the largest tumor area was used. Tumor size was defined as the product of the two largest perpendicular tumor diameters. Complete response (CR) was defined as disappearance of all contrastenhancing tumor on two subsequent scans at least 1 month apart, and the patient being off steroids and neurologically stable or improved. Partial response (PR) was defined as a > _ 50% reduction in cross-sectional contrast-enhancing tumor area on two subsequent scans at least 1 month apart, steroids stable or decreased and neurologically stable or improved. Progressive disease (PD) was defined as a >25% increase in crosssectional contrast-enhancing tumor area, new tumor on MRI or neurological deterioration, and steroids stable or increased. All other situations maintained for at least 3 months were considered stable disease (SD). All patient scans in which a response (CR or PR) was reported were centrally reviewed by an independent expert (K.H.X).
Secondary end points were overall survival (OS), progression-free survival (PFS) and safety of treatment. OS was measured from the date of study entry to the date of death or last follow-up. PFS was measured from the date of study entry to the first sign of radiological or clinical progression, whichever came first. Survival and PFS are reported separately for the intention-to-treat (ITT) and eligible population. Estimates of OS and PFS were derived by the Kaplan-Meier method. Log-rank tests were used to compare OS and PFS between groups. Hematological and nonhematological toxicities were assessed using the National Cancer Institute Common Toxicity Criteria.
Results

Patients
Forty patients were enrolled between March 2000 and May 2002, and these patients constitute the ITT population. Three patients were ineligible (two because of inappropriate histological material and one because of non-measurable disease), 39 patients were assessable for response, and all patients were assessable for survival and safety. Patient demographics and baseline disease characteristics are outlined in Table 1 . The median age was 61 years and one-third of the patients had a KPS of 60. Surgery was limited to biopsy for all patients. The median time from diagnosis to chemotherapy was 13 days (range 5-32).
Treatment delivery
Treatment delivered is reported in Table 2 . There were no discontinuations because of toxicity. Sixty per cent of the patients completed the planned four cycles of BCNU + temozolomide prior to RT, and the remaining patients experienced early disease progression after one (16%), two (16%) or three (8%) cycles. Dose reduction was requested in 31 of 162 (19%) cycles administered. Cycle 1 was administered at full dose for all patients; therefore, dose reduction took place in 31 of the remaining 122 cycles delivered. Doses were reduced for 13 of 34 patients who received more than one cycle. RT, radiotherapy; PD, progressive disease. Therapeutic RT was completed in 31 (78%) patients; only two patients were unable to complete RT because of early major clinical and radiological disease progression. In the remaining seven cases, RT was not given because of the patient's clinical status and anatomical considerations (e.g. large volumes to be irradiated, multifocal lesions in four cases and large corpus callosum tumors in three cases). Fourteen patients received maintenance chemotherapy after RT, including five patients who completed five cycles, three who completed six cycles, three who completed seven cycles, and three who completed eight cycles of BCNU + temozolomide.
Tumor response
By ITT analysis, 17 [42.5%; 95% confidence interval (CI) 27% to 58%] patients achieved an objective response to neoadjuvant BCNU + temozolomide, including two (5%) patients with a CR and 15 (37.5%) patients with a PR. In addition, nine (22.5%) patients had SD and 14 (35%) had PD. In the eligible population (n = 37), the objective response rate was 46% (95% CI 30% to 62%), including 5% CR and 41% PR. All these responses were confirmed at least 6 weeks apart and were maintained at least until the start of RT. Most of the responses (16 of 17) occurred during the first three cycles (i.e. within the first 4.5 months); objective responses were observed after one cycle in five patients, after two cycles in four patients and after three cycles in seven patients. Objective response was observed in two of seven (29%) patients with corpus callosum tumors, in four of 10 (40%) patients with multifocal tumors and in 11 of 23 (48%) patients with lobar tumors.
Survival
Median follow-up was 18.8 months (range 6-33.5) for the entire population. Based on ITT analysis, median OS was 12.7 months (Figure 1) , and the 12-and 18-month survival rates were 54% (95% CI 37.6% to 70.3%) and 20% (95% CI 5.7% to 34.9%), respectively. Results were similar in the ITT and eligible patient populations (Table 3) . At the time of analysis, a total of 10 (25%) patients were alive. The median follow-up of these patients was 12.7 months (range 6-29). Based on ITT analysis, median PFS was 7.4 months (Figure 2 ) [26] . Among patients with an objective response (CR or PR), median OS was 16.6 months and median PFS was 10.3 months (Table 3) .
Prognostic factors
Of the potential factors affecting prognosis (i.e. age, KPS, tumor size and tumor location), only age appeared to significantly influence survival, with an OS of 16.6 months for patients < _ 50 years of age and 9.8 months for patients >50 years of age (P = 0.032). However, tumor location (i.e. lobar versus multifocal versus corpus callosum) also showed a trend toward influencing survival, but did not reach statistical significance. An analysis of patients according to the recursive partitioning analysis (RPA) prognostic classes, which are based on the Radiation Therapy Oncology Group database of patients with malignant gliomas [27] , revealed that patients in this study who were classified as RPA V (n = 18) had longer survival rates (median OS 14 months; 2-year survival rate 15.1%; 95% CI 0% to 39.3%) than patients classified as RPA VI (n = 11) (median OS 5.3 months; 2-year survival rate 0%).
Safety
A total of 162 cycles of BCNU + temozolomide were administered. Treatment was well tolerated and was administered at full dose to 27 of 40 (68%) patients. No patient died of toxicity. There were 32 grade 3 or 4 adverse events, including 13 grade 4 adverse events all related to myelosuppression (Table 4) . These grade 4 events affected only six patients in the study. Platelet transfusions were administered seven times in four patients. Hospitalization for toxicity was required for three patients. No clinically relevant pulmonary complication Figure 1 . Kaplan-Meier estimate of overall survival in months from time of study entry.
was observed, and carbon monoxide diffusion capacity performed on 12 patients did not identify any significant alteration.
Discussion
The primary goal of this study was to evaluate the efficacy of the BCNU + temozolomide combination as neo-adjuvant therapy in GBM prior to RT. In the neo-adjuvant setting, the goal of chemotherapy is to reduce tumor burden, which may improve response to subsequent RT. Therefore, objective response is the most relevant end point in this setting. This regimen demonstrated promising antitumor activity, with an objective response rate of 42.5% (ITT analysis), which is particularly encouraging considering that this was a poor prognosis group of patients with unresectable GBM and considering that all responses were confirmed 1 month apart and were independently reviewed.
The observed response rate in this study compares favorably with that of other agents and regimens that have been explored as neo-adjuvant therapy in patients with high-grade gliomas (Table 5) . In this setting, reported response rates to chemotherapy in patients with mainly GBM varied from 16% to 54% [8 -14, 28, 29] . The combination of BCNU plus cisplatin has been the most frequently evaluated regimen. Surprisingly, four studies that explored a similar monthly schedule (BCNU 40 mg/m 2 and cisplatin 40 mg/m 2 , both on days 1-3) in unselected patient populations demonstrated response rates that varied widely, from 16% to 54% [8, 13, 28, 29] . Two other studies tested a platinum-based combination that included etoposide (VP16), with or without fotemustine, which demonstrated response rates of 27% and 24%, respectively [11, 12] . Finally, two studies testing single-agent temozolomide using the standard 5-day schedule have reported high response rates of 42% and 51% in patients with GBM [10, 14] . Although the response rate achieved in the current study with the combination of BCNU + temozolomide is similar to that achieved with temozolomide alone, the majority (60% to 70%) of patients in the two studies of single-agent temozolomide had subtotal resection of their tumors prior to chemotherapy, potentially affecting the response rate. In assessing the effect of neo-adjuvant BCNU + temozolomide on survival, it must be noted that patients in the current study presented with several factors associated with poor prognosis for survival (i.e. unresectable and multifocal disease, median age of 61 years and median KPS of 70). In fact, most patients (73%) in our study would be classified in RPA class V or VI. In the original cohort published by Curran et al. [27] , patients in class V (n = 395) had a median survival of 8.9 months, and patients in class VI (n = 263) had a median survival of 4.6 months. In comparison, patients in the current study who would be classified as RPA class V (n = 18) had a median survival of 14 months, and patients in RPA class VI (n = 11) had a median survival of 5.3 months. Therefore, although direct comparisons between these patient populations are difficult because of differences in selection criteria and changes in histological criteria, our data suggest that neo-adjuvant BCNU + temozolomide may provide a survival benefit in these poor prognosis patients. In addition, the overall median survival of 12.7 months reported in the current study compares favorably with previous studies in patients with inoperable GBM that reported median survivals of only 7 months with conventional RT [30] , 8.6 months with a combination of RT plus carboplatin and nicotinamide [31] and 10 months with neo-adjuvant chemotherapy (fotemustine, cisplatin and VP16) followed by conventional RT, as reported by Frenay et al. [12] (Table 5) . Our results also compare favorably with the combination of temozolomide and RT reported by Stupp et al. [7, 15] . In these trials, only 20% of patients presented with inoperable tumors, and median survival in this subset was only 5.3 months in the phase II trial [15] and 9.4 months in the phase III trial [7] .
PFS and OS in the current study also appear better than those seen in studies of single-agent temozolomide. For example, in the recent study reported by Gilbert et al. [14] ( Table 5) , median PFS was 3.9 months and median OS was 13.2 months. These values are not significantly improved compared with historical controls considering that only 39% of patients had inoperable tumors and 86% of patients had KPS > _ 80. In comparison, we have shown that BCNU + temozolomide in patients with unresectable tumors and poor performance status yielded a median PFS of 7.4 months in the ITT population and a median survival of 12.7 months. Moreover, among patients achieving an objective response, median PFS was 10.3 months. Ultimately, these considerable delays in disease progression may translate into a survival benefit.
In the poor prognosis patient population enrolled in this study, only age demonstrated prognostic significance, whereas tumor location tended to influence survival but not significantly. These results confirm that GBM constitutes a heterogenous group of tumors and suggest that a significant proportion of tumors are chemosensitive independent of age, KPS or surgery. These results are in accordance with the meta-analysis conducted by Stewart [6] , in which the benefit of adjuvant chemotherapy was independent of these prognostic factors. This underlines the necessity to determine appropriate molecular markers of sensitivity or resistance to treatment in order to better characterize tumors and determine the most effective treatment strategy for each individual patient.
Taken together, the results of this study suggest that the combination of BCNU and temozolomide, using the particular schedule investigated, may offer some benefit over singleagent temozolomide or BCNU. The treatment benefit associated with this combination may be related to modulation of AGAT activity consistent with preclinical and phase I clinical data, as suggested by Hammond et al. [24] . However, there remains some uncertainty about the clinical relevance of measuring AGAT activity in peripheral blood mononuclear cells, the correlation between AGAT depletion and sensitivity to methylating agents, and the relative impact of AGAT levels compared with other resistance mechanisms such as aberrant mismatch repair. Other strategies to maximize AGAT depletion with a continuous daily dosing schedule of temozolomide are under evaluation and will include correlation to AGAT levels in tumor tissue [24, 32] . In the current study, because of the limited tumor material obtained from stereotactic biopsies, these correlative studies could not be performed. Our results also showed that administration of BCNU on day 1 of each 5-day course of temozolomide was well tolerated; 60% of patients completed the planned four cycles of neo-adjuvant therapy, and none discontinued because of toxicity. Moreover, dose reductions were required in only 25% of cycles beyond cycle 1. In contrast, when neo-adjuvant BCNU and temozolomide were both administered on day 1, substantial toxicity was observed (Table 6 ) [22, 23] . In one study, 32% of patients developed grade 4 myelosuppression and dose reduction was required in 67% of cycles beyond cycle 1 [22] . In a similar study, 46% of patients experiencing grade 3 or 4 thrombocytopenia, and there were two toxic deaths [23] . Of the 41 eligible patients, nine (22%) patients discontinued early because of toxicity and 14 of 24 patients who completed the four planned cycles required dose reductions.
In conclusion, the combination of BCNU + temozolomide before RT, using a schedule that improved compliance compared with the 1-day schedule, exhibited promising clinical activity in unresectable GBM. Therefore, this regimen warrants further evaluation in malignant gliomas. While the combination of RT and temozolomide, as described by Stupp et al. [7] , may become the new standard for adjuvant therapy following surgical resection, some subgroups of patients, such as those with unresectable tumors, may benefit from neo-adjuvant therapy to reduce tumor burden before standard adjuvant RT. This provides an opportunity to evaluate new treatment strategies. 
